NPPA

Price regulator NPPA reviewed the maximum prices for five programmed drug formulations used in the treatment of various ailments, including seizures, epilepsy and allergic rhinitis, among others.

The National Pharmaceutical Pricing Authority (NPPA) has set price caps for an additional 15 drugs, including those used for the treatment of heart disease, infections, cancer, hypertension and pain relief.

As a result of price restrictions imposed by the National Pharmaceutical Pricing Authority (NPPA), India's drug pricing regulator, earlier this year, many multinational stent manufacturers are considering withdrawing their products from high Range of the country by citing "non-viability".

National drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has issued Guideline and Standard Operating Procedure for disposal of such review cases.

The national drug price regulator National Pharmaceutical Pricing Authority (NPPA) unearthed a total of 613 cases of non-compliance of its notified price ceilings of various drugs by companies.

Since after setting stent ceiling prices on February 14, 2017, the drug price regulator has so far received 40 written complaints against major hospitals.

National drug pricing authority NPPA has identified 634 cases where non-compliance with the notified price ceilings is suspected, Parliament has been informed.

More than 20 medical devices that are notified as "drugs" must all carry the maximum retail price on packages, the NPPA drug price regulator said. These devices include cardiac valves, surgical dressings, condoms, stents, disposable hypodermic syringes and orthopedic implants.

The NPPA drug price regulator has reduced the prices of anticancer drugs by almost 86% since last March to relieve patients. There has been "a significant reduction in the prices of cancer drugs since March 2016," said the National Pharmaceutical Pricing Authority (NPPA) in a tweet.